Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ENROLLING BY INVITATION
NCT07713498

Tapering of Inhaled Corticosteroids in Tezepelumab-treated Asthma patieNts: Impact on Clinical Outcomes: Inhaled Corticosteroids Will be Tapered According to Standard Care, in Severe Asthma Patients Which Have Started Treatment With Tezepelumab

Sponsor: Franciscus Gasthuis

View on ClinicalTrials.gov

Summary

To evaluate the relationship between starting tezepelumab treatment followed by tapering of inhaled corticosteroid (ICS) and ICS dose, metabolic outcomes, asthma control and exacerbation rate in a real world setting

Official title: TITANIC - Tapering of Inhaled Corticosteroids in Tezepelumab-treated Asthma patieNts: Impact on Clinical Outcomes

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

61

Start Date

2026-05-01

Completion Date

2027-10

Last Updated

2026-07-20

Healthy Volunteers

No

Conditions

Interventions

OTHER

Tapering of inhaled corticosteroid (ICS) treatment

All patients that have started tezepelumab treatment are eligible for tapering of ICS, since it is part of standard care.

Locations (1)

Franciscus Gasthuis & Vlietland

Rotterdam, South Holland, Netherlands